A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen

NCT02066636 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1428

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Nivolumab

Sponsor

Bristol-Myers Squibb